These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Murphy DL; Mueller EA; Hill JL; Tolliver TJ; Jacobsen FM Psychopharmacology (Berl); 1989; 98(2):275-82. PubMed ID: 2502799 [TBL] [Abstract][Full Text] [Related]
30. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615 [TBL] [Abstract][Full Text] [Related]
31. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Seibyl JP; Krystal JH; Price LH; Woods SW; D'Amico C; Heninger GR; Charney DS Psychiatry Res; 1991 Sep; 38(3):227-36. PubMed ID: 1754635 [TBL] [Abstract][Full Text] [Related]
32. Hormonal responses to meta-chlorophenylpiperazine (m-CPP) are undiminished by acute m-CPP pretreatment. Coccaro EF; Kavoussi RJ; Trestman RL; Gabriel SM; Cooper TB; Siever LJ Psychiatry Res; 1996 May; 62(2):139-45. PubMed ID: 8771611 [TBL] [Abstract][Full Text] [Related]
33. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034 [TBL] [Abstract][Full Text] [Related]
34. 5-HT1A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test. Leone M; Attanasio A; Croci D; Ferraris A; D'Amico D; Grazzi L; Nespolo A; Bussone G Neuroreport; 1998 Aug; 9(11):2605-8. PubMed ID: 9721941 [TBL] [Abstract][Full Text] [Related]
35. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Charney DS; Woods SW; Goodman WK; Heninger GR Psychopharmacology (Berl); 1987; 92(1):14-24. PubMed ID: 3110824 [TBL] [Abstract][Full Text] [Related]
36. Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects. Broocks A; Meyer T; Gleiter CH; Hillmer-Vogel U; George A; Bartmann U; Bandelow B Psychopharmacology (Berl); 2001 May; 155(3):234-41. PubMed ID: 11432685 [TBL] [Abstract][Full Text] [Related]
37. Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects. Kahn RS; Kling MA; Wetzler S; Asnis GM; van Praag H Psychopharmacology (Berl); 1992; 108(1-2):225-8. PubMed ID: 1410142 [TBL] [Abstract][Full Text] [Related]
38. Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects. Lawlor BA; Sunderland T; Hill JL; Mellow AM; Molchan SE; Mueller EA; Jacobsen FM; Murphy DL Psychiatry Res; 1989 Jul; 29(1):1-10. PubMed ID: 2772095 [TBL] [Abstract][Full Text] [Related]
39. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. Mueller EA; Murphy DL; Sunderland T J Clin Endocrinol Metab; 1985 Dec; 61(6):1179-84. PubMed ID: 4055985 [TBL] [Abstract][Full Text] [Related]
40. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]